NRXN1 as a novel potential target of antibody-drug conjugates for small cell lung cancer.

a.sfakia shared this article with you from Inoreader NRXN1 as a novel potential target of antibody-drug conjugates for small cell lung cancer. Via Oncotarget,Albany, N.Y. : Impact Journals,http://www.impactjournals.com/oncotarget/ NRXN1 as a novel potential target of antibody-drug conjugates for small cell lung cancer. Oncotarget. 2020 Sep 29;11(39):3590-3600 Authors: Yotsumoto T, Maemura K, Watanabe K, Amano Y, Matsumoto Y, Zokumasu K, Ando T, Kawakami M, Kage H, Nakajima J, Yatomi Y, Nagase T, Takai D Abstract Small cell lung cancer (SCLC) is a high-grade malignancy, and treatment strategies have not changed for decades. In this study, we searched for novel targets for antibody-drug conjugate (ADC) therapy for SCLC. We identified transmembrane proteins overexpressed specifically in SCLC with little or no expression in normal tissues and decided to focus on the cell adhesion molecule neurexin-1 (NRXN1). The cell surface overexpression of NRXN1 was confirmed using flow cytometry in SCLC cell lines (SHP77 and NCI-H526). The combination of a primary anti-NRXN1 monoclonal antibody and a secondary ADC exhibited anti-tumor activity in SCLC cell lines. Moreover, the knockout of NRXN1 in SHP77 cells resulted in a loss of the anti-tumor activity of NRXN1-mediated ADC therapy. Thus, NRXN1 could be a novel target for ADC therapy for the treatment of SCLC that is worth further research. PMID: 33062195 [PubMed] View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.